Lifeboat Foundation

Living in a culture dependant upon caffeine and lack of sleep, its important to remember that sleep offers an incredibly important biological function. One night of sleep deprivation is tied to Alzheimer’s disease.

While people once believed that sleep was merely a period of inactivity and rest, modern studies in chronobiology have shown that sleep is important for a variety of biochemical processes. A recent study suggests that sleep is even more important than physicians and scientists previously thought, allowing the brain to flush out toxic chemicals that build up over the course of a day.

Neurotoxins and Your Brain

Continue reading “Neurotoxins and Sleep: What You Need to Know” »

What if a large class of algorithms used today—from the algorithms that help us avoid traffic to the algorithms that identify new drug molecules—worked exponentially faster?

Computer scientists at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have developed a completely new kind of algorithm, one that exponentially speeds up computation by dramatically reducing the number of parallel steps required to reach a solution.

The researchers will present their novel approach at two upcoming conferences: the ACM Symposium on Theory of Computing (STOC), June 25–29 and International Conference on Machine Learning (ICML), July 10 −15.

Continue reading “‘Breakthrough’ algorithm exponentially faster than any previous one” »

Maryam shanechi, university of southern california.

With recent technological advances, we can now record neural activity from the brain, and manipulate this activity with electrical or optogenetic stimulation in real time. These capabilities have brought the concept of brain-machine interfaces (BMI) closer to clinical viability than ever before. BMIs are systems that monitor and interact with the brain to restore lost function, treat neurological disorders, or enhance human performance.

Continue reading “The State of Brain-Machine Interfaces” »

The medication can reduce the duration of symptoms.

• By Helen Branswell, STAT on June 28, 2018

Polio was a devastating disease before the development of the polio vaccine. But now, this once-feared virus might help treat another deadly illness — brain cancer.

In a new study, some patients who had an aggressive type of brain cancer called glioblastoma and who received a genetically modified poliovirus lived much longer than typical for these patients.

The study found that about 21 percent of the brain cancer patients who received the poliovirus therapy were alive three years later. In contrast, among a group of previously treated patients who had the same cancer but received standard therapies (such as chemotherapy), just 4 percent were alive after three years.

Continue reading “Once-Dreaded Poliovirus Could Treat Brain Cancer” »

Does anyone have an opinion on this latest finding?

In the largest-ever study of its kind, researchers combined genomic data from nearly 900,000 patients and healthy individuals to identify commonalities among 10 mental illnesses.

Sandia Laboratories is developing iron nanoparticles as tracer elements to track metastasized cancer tumors…

It’s taken 15 years to devise a way to make iron nanoparticles all the same size, but the rewards could be timeless.

Every three seconds, a person somewhere in the world breaks a bone due to osteoporosis—a progressive disease that decreases bone density, making bones weak and fragile. Osteoporotic fractures greatly reduce quality of life, and immobilization following a fracture can lead to further bone loss which puts these patients at risk for breaking another bone.

When SpaceX CRS-11 launched to the space station last June, it carried 40 mice to the ISS National Lab for a mission aimed at improving treatment for the millions of people with osteoporosis back on Earth. The Rodent Research (RR)-5 mission successfully proved the robustness of a new potential osteoporosis therapy based on a naturally produced protein, NELL-1, and also led to significant improvements in the delivery of the therapy.

Dreeming big.

Dreem Announces $35 Million Financing from lead investors Johnson & Johnson Innovation and Bpifrance (press release):

“Dreem, a neurotechnology company, today announced the closing of a new round of funding, raising $35 million USD to rapidly accelerate product development, invest in strategic research and development, and advance the future of sleep technology. Last year, Dreem introduced a comprehensive solution to address a suite of sleep problems and enhance the quality of rest during the night. The Dreem headband monitors brain activity to track sleep accurately and uses auditory stimulation as a medium to help people fall asleep faster, get deeper sleep, and wake up refreshed.

Continue reading “Sleep-focused neurotech firm Dreem raises $35M from Johnson&Johnson Innovation and Bpifrance” »